Retrophin Inc. (RTRX) announced Wednesday morning that its Phase 2 study of sparsentan, for the treatment of focal segmental glomerulosclerosis, achieved statistical significance in the primary efficacy endpoint.
from RTT - Before the Bell http://ift.tt/2c0qYoq
via IFTTT
No comments:
Post a Comment